diroximel fumar less gi side effect across board avoid
discontinu worth million annual
announc posit top-line result studi diroximel
fumar novel oral fumar distinct chemic structur tecfidera
specif differ leav group prodrug design less irrit
patient gi system potenti releas activ moieti
favor posit gi system overal gi side effect much better
new formul measur patient report gi side effect overal view
result posit tecfidera-famili franchis biggest next
step result tecfidera ipr process expect read month
detail result diroximel fumar statist superior tecfidera
primari endpoint self-report day gastrointestin gi symptom intens
score use igisi rate scale lower new drug
common advers event report studi treatment group
lower diroximel fumar
commerci ramif overal proport patient lead studi
discontinu diroximel fumar dimethyl fumar
importantli proport patient discontinu due gi advers event
five-week treatment period diroximel fumar
dimethyl fumar note discontinu number much lower
real world discontinu number tecfidera real world report
howev simpli appli clinic trial discontinu
ratio real world real world discontinu rate diroximel
note billion tecfidera run rate
million view reason estim diroximel fumar
explicitli model combin franchis
step involv ipr februari mylan ipr cover patent
mg dose institut signal pto believ reason
chanc one claim overturn see page thought
valuat valu dcf discount rate tg
idc btig estim compani document
million except per share amount
downgrad buy neutral null aducanumab readout march make appropri
updat model recogn lead compani neurolog space seem
significantli behind develop gene therapi like novarti nv rate voyag
buy therapeut get mab protein across blood brain barrier like denali approach
tecfidera front buy analyst timothi chiang ipr cover patent like continu
weigh next month
anti-tau mab psp data
cle/sl data
natalizumab epilepsi data
opicinumab ms data
asyn mab parkinson diseas data
manag guidanc flat sale two year follow increas
base princip launch vumer
po adopt price point
spinraza conserv model attrit sale growth follow market
entri zolgensma risdiplam
zolgensma risdiplam significantli erod spinraza sale
neg ipr decis overturn tecfidera patent
potenti zolgensma risdiplam launch significantli erod spinraza sale
global
biopharmaceut compani
discov develop
commerci therapi
tecfidera tysabri avonex
plegridi headquart
cambridg found
case favor biogen believ burden proof intern pto discuss preponder evid
like true said patent scrutin twice found legitim patent
new argument includ baselin correct clinic trial data suggest mg mg dose
activ mg dose protect obviou correct baselin field effect baselin
imbal imperfectli defin educ guess best remind prior art need describ invent
licens experi accordingli put chanc model explicitli file
respons anticip mylan respons file septemb institut decis expect
februari reveal earn call anda recent withdrawn suggest
settlement may close noth confirm far
btig cover compani mention report
appendix analyst certif import disclosur
